Probiotics and inflammatory bowel disease;Probióticos y enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 25, Issue 9, 2002, Pages 552-559

  Borruel, N ^a   Casellas, F ^a   Guarner, F ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; CLARITHROMYCIN; METHYLPREDNISOLONE; METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; TOBRAMYCIN; VANCOMYCIN;

BACTERIAL FLORA; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; ENTERITIS; ESCHERICHIA COLI; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INTESTINE FLORA; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; PATHOGENESIS; REVIEW; SALMONELLA; YERSINIA;

EID: 0036871717     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-5705(02)70312-9     Document Type: Review

References (77)

1. Rutgeerts P, Geboes K, Peeters M, Hiele M, Penninckx F, Aerts R, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;2:771-4.
2. D'Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions caused by infusion of intestinal contents in excluded ileum in Crohn's disease. Gastroenterology 1998;114:262-7.
3. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115:182-205.
4. Chiodini RJ, Kruiningen HJV, Thayer WR, Merkal RS, Coutu JA. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 1984;29:1073-9.
5. Thayer WR, Coutu JA, Chiodinni RJ, Kruiningen HJV, Merkal RS. Possible role of mycobacteria in inflammatory bowel disease (II). Mycobacterial antibodies in Crohn's disease. Dig Dis Sci 1984;29:1080-5.
6. Kobayashi K, Brown WR, Brennan PL, Blaser MJ. Serum antibodies to mycobacterial antigens in active Crohn's disease. Gastroenterology 1988;94:1401-11.
7. Kobayashi K, Blaser MJ, Brown WR. Immunohistochemical examination for mycobacteria in intestinal tissues from patients with Crohn's disease. Gastroenterology 1989;96:1009-15.
8. Sanderson JD, Moss MT, Tizard MLV, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut 1992;33:890-6.
9. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobaacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513-8.
10. Swift GL, Srivastava ED, Stone R, Pullan RD, Newcombe RG, Rhodes J, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994;35:363-8.
11. Tabaqchali S, O'Donoghue DP, Bettleheim KA. Escherichia coli antibodies in patients with inflammatory bowel disease. Gut 1978;19:108-13.
12. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998;115:1405-13.
13. Masseret E, Boudeau J, Colombel JF, Neut C, Desreumaux P, Joly B, et al. Genetically related Escherichia coli strains associated with Crohn's disease. Gut 2001;48:320-5.
14. Wakefield AJ, Sankey EA, Dhillon AP, Sawyer AM, More L, Sim R, et al. Granulomatous vascultis in Crohn's disease. Gastroenterology 1991;100:1279-87.
15. Wakefield AJ, Pittilo RM, Sim R, Cosby SL, Stephenson JR, Dhillon AP, et al. Evidence of persistent measles virus infection in Croh's disease. J Med Virol 1993;39:345-53.
16. Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994;334: 508-10.
17. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995;345:1071-4.
18. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001;48:132-5.
19. Swidsinski A, Ladhoff A, Pernhaler A, Swidsinski S, LoeningBaucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
20. Braun J. Unsettling facts of life: bacterial commensalism, epithelial adherence and inflammatory bowel disease. Gastroenterology 2002;122:228-9.
21. Videla S, Vilaseca J, Guarner F, Salas A, Treserra F, Crespo E, et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994;35:1090-7.
22. Videla S, Vilaseca J, Guarner F, Salas A, González G, Antolín M, et al. Stimulation of mucosal inflammatory activity by the normal fecal flora in a rat model of colitis. Inflammatory Bowel Dis 1997;3:191-7.
23. García-Lafuente A, Antolín M, Guarner F, Crespo E, Salas A, Forcada P, et al. Incrimination of anaerobic bacteria in the induction of experimental colitis. Am J Physiol 1997;272:G10-5.
24. Mourelle M, Salas A, Guarner F, Crespo E, García-Lafuente A, Malagelada JR. Stimulation of transforming growth factor-β1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 1998;114:519-26.
25. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995;102:448-55.
26. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interlukin-10 or antibodies to interleuklin-12. Eur J Immunol 1996;26:934-8.
27. Ehrhardt RO, Ludviksson BR, Gray B, Neurath M, Strober W. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997;158:566-73.
28. Kühn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
29. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365-75.
30. Duchmann R, Neurath MF, Meyer zum Büschenfelde KH. Responses to self and non-self intestinal microflora in health and inflammatory bowel disease. Res Immunol 1997;148:589-94.
31. Casellas F, Borruel N, Papo M, Guarner F, Antolin M, Videla S, et al. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 1998;4:1-5.
32. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118:S68-82.
33. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380-4.
34. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as adjunct to corticoids in severe ulcerative colitis. Gut 1986;27:1210-2.
35. Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123-9.
36. Lobo AJ, Burke DA, Sobala GM, Axon AT. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther 1993;7:155-8.
37. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994;89:43-6.
38. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220-1.
39. Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, et al. A prospective randomised controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92:454-6.
40. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001;36:971-4.
41. Turunen UM, Färkkilä MA, Hakala K, Seppala K, Sivonen A, Ogren M, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072-8.
42. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
43. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-40.
44. Rutgeers P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
45. Colombel JF, Lemman M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol 1999;94:674-8.
46. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998;12:53-6.
47. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled trial of metronidazole plus ciprofloxacin. A J Gastroenterol 1996:91:328-32.
48. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther 2000;14:801-6.
49. Colombel JF, Cortot A, Van Kruiningen HJ. Antibiotics in Crohn's disease. Gut 2001;48:647.
50. Guarner F, Schaafsma G. Probiotics. Int J Food Microbiol 1998;39:237-8.
51. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120:622-35.
52. Milner JA. Functional foods and health promotion. J Nutr 1999;129:S1395-7.
53. Shanahan F. Probiotics in inflammatory bowel disease. Gut 2001;48:609.
54. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000;6:107-15.
55. Borruel N, Carol M, Casellas F, Antolfn M, De Lara F, Espfn E, et al. Increased mucosal TNFα production in Crohn's disease can be modulated in vitro by probiotic bacteria. Gut 2002; 5:659-64.
56. Fabia R, Ar'Rajab A, Johansssib ML, Willen R, Andersson R. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic-acid induced colitis in the rat. Scand J Gastroenterol 1993;28:155-62.
57. Mao Y, Nobaeck S, Kasravi B, Adawi D, Stenram U, Molin G, et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 1996; 111:334-44.
58. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10 deficient mice develop chronic enterocolitis. Cell 1993; 75:263-74.
59. Sellon RK, Tonkonogy SL, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10 deficient mice. Infect Immun 1998;66: 5224-31.
60. Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 2000;118:1094-105.
61. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
62. Madsen K, Cornish A, Soper P, Mc Kaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121: 580-91.
63. O'Mahony, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgibbon J, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001;15:1219-25.
64. Kennedy RJ, Hoper M, Deodhar K, Kirk SJ, Gardiner KR. Probiotic therapy fails to improve gut permeability in a hapten model of colitis. Scand J Gastroenterol 2000;35:1266-71.
65. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine collitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-5.
66. Shanahan F. Turbo probiotics for IBD. Gastroenterology 2001;120:1297-8.
67. Videla S, Vilaseca J, Antolín M, García-Lafuente A, Guarner F, Crespo E, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol 2001; 96:1486-93.
68. Malin M, Soumalainen H, Saxelin M, Isolauri E. Promotion of Ig A immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996:40:137-45.
69. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31:453-7.
70. Plein K, Hotz J. Therapeutic effect of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea-a pilot study. Z Gastroenterol 1993;31:129-34.
71. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
72. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
73. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
74. Faubion WA, Sandborn WJ. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad. Gastroenterology 2000;118:630-1.
75. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
76. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13: 1103-8.
77. Sartor RB. Probiotics in chronic pouchitis: restoring luminal microbial balance. Gastroenterology 2000;119:584-6.